676 results found | searching for "pharma"

First Previous 3 4 5 6 7 8 9 10 11 12 Next Last 
  • kenrox
  • Kenrox Healthcare is offering Gynae PCD Pharma Franchise Company In India. Our all products are WHO-ISO-GMP Certified. Visit Here : https://kenrox.in/gynae-pcd-pharma-franchise-company-in-india/
  • kenrox
  • Kenrox Healthcare is providing PCD Pharma Franchise in PAN India. Contact us to get information about Why Is PCD Pharma Franchise A Good Option For Business Startup. PCD Pharma Franchise is a very good option to start a business. Contact us if you want to start PCD Pharma Franchise Business. Visit Here : https://kenrox.in/why-is-pcd-pharma-franchise-a-good-option-for-business-startup/
  • kenrox
  • Start PCD Pharma Franchise Business and want to Take PCD Pharma Franchise from Pharma Company then Kenrox Healthcare is providing you very best products. Visit Here : https://kenrox.in/how-can-i-take-franchise-of-pharma-company/
  • jameshebrew
  • The biopharmaceutical contract manufacturing market is projected to grow at a CAGR of 10% during 2022-2035, claims Roots Analysis With the advent of novel technologies and rising preference for such therapeutic interventions, biologics have made a significant impact in the pharmaceutical domain, delivering a ground-breaking treatment regimen for a myriad of disease indications. London Roots Analysis has announced the addition of the “Biopharmaceutical Contract Manufacturing Market, 2022–2035” report to its list of offerings. In pursuit of both time and cost savings, as well as to access higher scales of production, outsourcing has emerged as a lucrative option for biologic drug developers. Driven by several blockbuster products, a burgeoning pipeline of biologic drugs, the demand for reliable contract service providers, which have the required expertise and advanced manufacturing capabilities, is expected to grow at a commendable pace in the coming years. Currently over 275 companies claim to be biopharma CDMO / biopharma CMO, in compliance with the regulatory standards. It is also worth highlighting that biopharmaceutical contract manufacturers are actively trying to consolidate their presence in this field by entering into strategic alliances in order to meet the indubitably rising demand for biologics. In 2021, a sum of over USD 70 billion was invested in the cell and gene therapy domain. However, biologics manufacturing is fraught with various challenges. To request a sample copy / brochure of this report, please visit this https://www.rootsanalysis.com/reports/250/request-sample.html Key Market Insights Presently, more than 275 players offer contract manufacturing services for biologics This segment of the industry is dominated by the presence of mid-sized players (51-200 employees) and start-ups / small players (2-50 employees), which collectively represent more than 80% of the total contract manufacturers. In addition, it is important to mention that about 33% of the firms were founded post 2010. Approximately 60% of the players carry out manufacturing operations across all scales of operation More than 60% of the service providers are engaged in manufacturing of recombinant proteins and peptides. This was followed by 49% CMOs that claim to have the required capabilities to provide antibody manufacturing services. It is worth mentioning that a number of biologic manufacturers in this domain have the required capabilities to provide manufacturing services for niche and upcoming classes of biologics, such as ADCs, cell therapies, gene therapies and plasmid DNA. 450+ manufacturing facilities dedicated to biologic-based therapies have been established globally North America has emerged as a key manufacturing hub for biotherapeutics, featuring the presence of nearly 33% of the total manufacturing facilities. This is followed by facilities located in Europe and Asia-Pacific. Prominent manufacturing hubs within Europe include (in decreasing order of number of facilities) Germany, the UK, France, Italy and Spain. 800 partnerships were established in this domain, during the period 2015-2022 Partnership activity of biologic contract manufacturers has increased at a CAGR of 42%, during the given period. Manufacturing agreements emerged as the most popular type of partnership model adopted by industry stakeholders (37%), followed by product development and manufacturing agreements (19%). Further, over 80% of the expansion projects undertaken by industry stakeholders were initiated since 2020. Currently, 54% of the overall, installed biopharmaceutical contract manufacturing capacity is for mammalian expression systems The maximum (49%) capacity is installed with players companies based in Asia-Pacific. It is worth mentioning that the aforementioned region has a higher number of players engaged in biopharmaceutical contract manufacturing, which have further established multiple production facilities. This is followed by the capacity available with players having headquarters in North America (25%) and Europe (24%). For additional details, please visit https://www.rootsanalysis.com/reports/view_document/biopharmaceutical-contract-manufacturing-market/250.html You may also be interested in the following titles: 1. Peptide Therapeutics: Contract API Manufacturing Market: Industry Trends and Global Forecasts, 2022-2035 2. Biopharmaceutical Excipient Manufacturing Market: Industry Trends and Global Forecasts, 2022-2035 Contact: Ben Johnson +1 (415) 800 3415 +44 (122) 391 1091 Ben.johnson@rootsanalysis.com [more]
  • jameshebrew
  • The pharmaceutical secondary packaging market is projected to grow at an annualized rate of 7.6% during the period 2022-2035, claims Roots Analysis In order to avail benefits, such as higher flexibility, reduced cost and assistance in meeting the rising demands, several pharmaceutical companies have demonstrated a preference to outsource their secondary packaging requirements to contract packaging organizations. Roots Analysis has announced the addition of “Pharmaceutical Secondary Packaging Market, 2022 – 2035” report to its list of offerings. The anticipated growth in the therapeutics pipeline is likely to translate into a significant rise in the demand for cost-effective and quality secondary packaging solutions, presenting lucrative opportunities for contract packaging organisations. Driven by the growth of the overall pharmaceutical industry and increasing preference of drug developers for outsourcing certain operations, the secondary packaging providers market is expected to witness a steady increase. Driven by the ongoing innovation in this field, continuous growth in the pharmaceutical drugs pipeline and a steady rise in drug approvals, the pharmaceutical secondary packaging market is likely to witness positive growth in the foreseen future. Key Market Insights Around 165 companies claim to offer pharmaceutical secondary packaging services, globally Majority (51%) of the industry stakeholders are headquartered in Europe, followed by those based in North America (37%) and Asia-Pacific (12%). In addition, close to 65% of the secondary packaging providers offer cartons, followed by companies offering boxes (53%) and other packaging formats, such as trays and pouches (29%). Partnership activity has grown at an annualized rate of ~85%, between 2018-2021 Maximum number of partnerships were observed in 2020 (29), indicating a recent increase in the partnership activity in this domain. Majority of these agreements were reported to be instances of acquisitions, representing over 45% of the total number of instances. Expansion activity in this domain has grown at a CAGR of ~55%, between 2018 and 2022 Most of such initiatives were focused on expanding the existing capacity (40%), followed by instances of establishing a new facility (38%) and facility expansions (13%). Further, majority of the investments were made in facilities located in North America (54%) and Europe (35%). Till 2035, annual demand for pharmaceutical packaging solutions is expected grow at a CAGR of ~8% Currently, Asia-Pacific and North America capture the majority share of the overall demand for pharmaceutical secondary packaging (~70%). By 2035, the demand for secondary packaging products is projected to reach over 200 billion units. Further, currently, the highest demand (95%) is generated via secondary packaging of vials and bottles. North America and Europe are anticipated to capture close to 60% of the market share, by 2035 In addition, the market in Asia-Pacific is likely to grow at a relatively faster pace (6.2%) in the long term. Further, in 2035, majority share (~95%) of the pharmaceutical secondary packaging revenues is likely to be generated from packaging of vials and bottles. To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/reports/pharmaceutical-secondary-packaging-market/request-sample.html Key Questions Answered • Who are the leading players engaged in the pharmaceutical secondary packaging domain? • What is the relative competitiveness of pharmaceutical secondary packaging providers? • Which types of partnership models are most commonly adopted by industry stakeholders? • What kind of expansion initiatives have been undertaken by pharmaceutical secondary packaging providers? • How is the current and future market opportunity likely to be distributed across key market segments? The financial opportunity within the pharmaceutical secondary packaging market has been analyzed across the following segments: • Type of Secondary Packaging • Boxes • Cartons • Pouches • Type of Primary Packaging Packed • Ampoules • Blister Packs • Bottles • Cartridges • Syringes • Vials • Key Geographical Regions • North America • Europe • Asia-Pacific • MENA • Latin America • Rest of the World The research includes profiles of key players (listed below); each profile features a brief overview of the company, details related to its pharmaceutical secondary packaging offerings, recent developments and an informed future outlook. • Catalent • Patheon (By Thermo Fisher Scientific) • PCI Pharma Services • Pfizer CentreOne • Sharp • Almac Group • Central Pharma • CordenPharma • Eurofins CDMO • Tjoapack • ABS (Australian Blister Sealing) • Bushu Pharma • CMIC • Kishore group • Prince Art Packages For additional details, please visit https://www.rootsanalysis.com/reports/pharmaceutical-secondary-packaging-market.html or email sales@rootsanalysis.com You may also be interested in the following titles: 1. Targeted protein degradation market, 2022-2035 2. Cell Therapy Manufacturing Market, 2021-2030 About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. Contact: Ben Johnson +1 (415) 800 3415 +44 (122) 391 1091 Ben.johnson@rootsanalysis.com [more]
  • globalpharma
  • Medicine Wholesalers in UK Global Pharma Distributor offers safe, secure and reliable pharmaceutical wholesale uk hospitals, clinics, the NHS and various other healthcare facilities. https://www.globalpharmadistributoruk.com/
  • jameshebrew
  • The site management organizations (SMO) market is projected to grow at an annualized rate of ~10% during the period 2021-2035, claims Roots Analysis The rapidly growing clinical pipeline and challenges associated with the conduct of clinical trials in a cost and time effective manner, has presented lucrative opportunities for service providers with expertise in clinical trial site management Roots Analysis has announced the addition of “Site Management Organizations (SMO) Market, 2021 – 2035” report to its list of offerings In recent years, drug / device developers have demonstrated a preference to continue relying on SMOs for conducting clinical trials in order to significantly optimize trial cost and research timelines. Driven by the steady growth in clinical research activity and inherent benefits offered by Site management organizations (SMO), the market opportunity for such players is projected to grow at a significant pace in the foreseen future. Key Market Insights Around 250 companies across the world claim to offer clinical trial site management services Majority (43%) of the industry stakeholders are headquartered in North America, followed by those based in Asia-Pacific (32%) and Europe (19%). In addition, 25% of the companies engaged in this domain offer site management services across the globe, followed by those providing services in Asia-Pacific (23%). 200+ partnerships were established in this domain, during the period 2016-2021 Service alliances (26%) and clinical trial agreements (23%) emerged as the most common types of partnership models adopted by stakeholders engaged in this domain. Nearly 65% of the deals in this domain were established after 2018, with the maximum activity being reported in 2021 (56). ~USD 1 billion invested in various domain focused initiatives, since 2015 Maximum number of funding instances (21%) were reported in 2021, amounting to USD 614 million in capital investments. A significant number of funding instances (43%) were venture capital rounds, followed by instances of other equity (29%) and grants (7%). Till 2035, annual demand for clinical trial study participants is expected grow at a CAGR of 8.2% Currently, North America and Asia-Pacific hold the majority share of the overall demand for clinical trial study participants (60%). By 2035, the demand for patients in clinical trial studies is projected to reach 25 million. Further, currently, the highest demand is generated via phase III trials (43%), followed by phase IV studies (38%). North America and Europe are anticipated to capture close to 65% of the market share, by 2035 In addition, in Asia-Pacific the Site Management Organization Market Growth is likely to be at a relatively faster pace (9%) in the long term. Further, in 2035, the majority share (~45%) of clinical trial site management revenues is likely to be generated from trials focused on phase III evaluation of clinical studies. To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/reports/site-management-organizations-market/request-sample.html Key Questions Answered • Who are the leading players engaged in the clinical trial site management domain? • What is the relative competitiveness of different site management organizations? • What type of partnership models are commonly adopted by stakeholders in this industry? • What is the capital investments trend in the site management organizations domain? • Which are the most active clinical trial centers? • What are the major market trends and driving factors that are likely to impact the growth of site management organizations market? • How is the current and future market opportunity likely to be distributed across key market segments? The financial opportunity within the SMOs market has been analyzed across the following segments: • Therapeutic Areas • Oncological Disorders • CNS Disorders • Infectious Diseases • Respiratory Disorders • Cardiovascular Diseases • Endocrine Disorders • Gastrointestinal Disorders • Musculoskeletal Diseases • Immunological Disorders • Others • Trial Phases • Phase I • Phase II • Phase III • Phase IV • Clinical Trial Components • Site Management • Onsite Monitoring • Project Management • Data Management • Regulatory Affairs • Logistics • Quality Control • Others • Types of Interventions • Therapeutics • Devices • Surgical Procedure • Key Geographical Regions • North America • Europe • Asia-Pacific • Latin America • MENA • Rest of the World The research includes profiles of key players (listed below); each profile features a brief overview of the company, details related to its site management service portfolio, recent developments and an informed future outlook. • FOMAT Medical Research • Parexel • Pharm-Olam • Veristat • WCCT Global • Worldwide Clinical Trials • CROMSOURCE • Fidelis Research • Scandinavian CRO • TFS HealthScience • Trialbee • CMIC • George Clinical • Tigermed • Veeda Clinical Research For additional details, please visit https://www.rootsanalysis.com/reports/site-management-organizations-market.html or email sales@rootsanalysis.com You may also be interested in the following titles: 1. Patient Recruitment and Retention Services Market (2nd Edition): Industry Trends and Global Forecasts, 2021-2030 2. Pharmaceutical Contract Research Services Market: Industry Trends and Global Forecasts, 2021-2030 About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact Information Roots Analysis Private Limited Ben Johnson +1 (415) 800 3415 ben.johnson@rootsanalysis.com [more]
  • prasaddhumal
  • The global inspection machines market is expected to bolster over the projection with a robust CAGR of 5.1% over the forecast period from 2022 to 2032. The global market is anticipated to be appraised at US$ 1,053.5 Mn by 2032, up from US$ 643.1 Mn in 2022. It has been observed that a surging number of inspection checkpoints are present throughout the production line. This is likely to drive the sales of inspection machines. Although, integrating inspection equipment into the manufacturing and packaging line is difficult because of the complexity of machines and the heightened end-use environment. Conversely, increasing investments in biotech and pharma research and development (R&D) activities are anticipated to generate remunerative opportunities for the market. Get More Insights On This Report:  https://www.futuremarketinsights.com/reports/inspection-machines-market [more]
  • Healthcare_medical
  • Oligonucleotide Synthesis Market worth $14.1 billion by 2026 https://www.marketsandmarkets.com/Market-Reports/oligonucleotide-synthesis-market-200829350.html The report "Oligonucleotide Synthesis Market by Product (Drug, Synthesized Oligos (Primer, Probe), Reagents), Type (Custom, Predesign), Application (Therapeutic (ASO, siRNA), Research (PCR), Diagnostic), End User (Hospital, Pharma, CROs) - Global Forecast to 2026", is projected to reach USD 14.1 billion by 2026 from USD 6.3 billion in 2021, at a CAGR of 17.6% during the forecast period. The major factors driving the growth of this market include the increasing use of synthesized oligos in therapeutic applications, increasing government funding, and the growing focus on personalized medicine. [more]
  • Healthcare_medical
  • Protein Expression Market worth $5.4 billion by 2027 https://www.marketsandmarkets.com/Market-Reports/protein-expression-market-180323924.html The report "Protein Expression Market by Type (E.Coli, Mammalian, CHO, HEK 293, Insect, Pichia, Cell-free), Products (Reagents, Vectors, Competent Cells, Instruments, Service), Application (Therapeutic, Industrial), End User, and Region - Global Forecast to 2027", is expected to reach USD 5.4 billion by 2027 from an estimated USD 2.9 billion in 2022 at a CAGR of 13.3%. Factors such as the increasing incidence of chronic diseases, increasing research activities on recombinant-based protein expression, growth in the life sciences and biopharmaceutical industries, as well as the availability of funding for protein-based research. However, the high cost of protein expression reagents and instruments is expected to restrain the growth of this market. [more]
First Previous 3 4 5 6 7 8 9 10 11 12 Next Last